Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434
about
Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureChildhood acute lymphoblastic leukemia: Integrating genomics into therapyNelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment.Rechallenging With Intrathecal Methotrexate After Developing Subacute Neurotoxicity in Children With Hematologic Malignancies.Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.Current status and future directions of T-lymphoblastic lymphoma in children and adolescents.JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children.Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.Persistent Multiyear Control of Relapsed T-Cell Acute Lymphoblastic Leukemia With Successive Donor Lymphocyte Infusions: A Case ReportThe genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.Severe Mucha-Habermann-Like Ulceronecrotic Skin Disease in T-Cell Acute Lymphoblastic Leukemia Responsive to Basiliximab and Stem Cell Transplant.Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.High-dose methotrexate vs. Capizzi methotrexate for the treatment of childhood T-cell acute lymphoblastic leukemia
P2860
Q26746934-055C72B6-9FFC-4CA0-B6C5-F06B338796BDQ28080463-F5F50644-D3DF-430C-AF57-1A89231F3B2CQ30240892-FBA451DE-8B01-4CD2-9851-1E3036531839Q37360025-6485DD58-E53E-44F6-AFB3-A83209998928Q38644266-78F1CDC4-0D12-4171-A302-B90A7D73F107Q38672607-A41FBB88-C45A-4328-81D8-4EC237966AADQ38673114-046F5DD9-0869-4844-BDDD-3F0EC75D1760Q38685482-9F9AE053-D81E-476A-9779-6B4F79C2C704Q38779952-670F3952-5A43-4415-98C6-91041FAF856BQ38796883-69356B27-30BB-4ED7-8AB2-CA7C90177ECEQ39041475-78BAA6DA-8974-49AE-95ED-BF8652CAE071Q40518805-A2F9554E-F04B-4B17-9D94-DBF3EAA9E33DQ41781135-C7181D83-312E-4D92-823F-BE683A3F1730Q41956972-8191B2C0-AAB6-417B-8693-BEFB45C8F07CQ45062542-63F4335A-7B8E-491E-9CBE-2401FC329B02Q45072276-2C512645-FD02-4BBC-80DD-E42D2434305DQ45985775-B5416AC8-DC47-4E84-9B2A-E50D64ABA82BQ46294823-C293C38B-6F74-4E4C-9A49-11A6FAD04C9EQ48105025-A4EE1481-2F18-4D75-BC9E-E720D6BE686EQ48298283-9083065E-CA68-4F13-B67D-F82E6C27C0BFQ50168849-65D87006-23E1-43EF-8991-03B343C6A2EDQ51738618-E5D0A60D-D78C-4CCA-AB31-F09FBEBA18B2Q52431551-1965556B-3E41-4DB5-86BD-703C06AE1DE7Q53713010-5B3FFB30-5EDF-4756-B317-DAE6A16F6D46Q54685770-9A2AB170-4FBD-4A38-B038-7D0827AB2A26Q58776389-B6A809F1-F163-477E-B4B9-6FE5BCCE58C5
P2860
Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Safe integration of nelarabine ...... Oncology Group Study AALL0434
@ast
Safe integration of nelarabine ...... Oncology Group Study AALL0434
@en
type
label
Safe integration of nelarabine ...... Oncology Group Study AALL0434
@ast
Safe integration of nelarabine ...... Oncology Group Study AALL0434
@en
prefLabel
Safe integration of nelarabine ...... Oncology Group Study AALL0434
@ast
Safe integration of nelarabine ...... Oncology Group Study AALL0434
@en
P2093
P2860
P50
P356
P1476
Safe integration of nelarabine ...... Oncology Group Study AALL0434
@en
P2093
Andrew J Carroll
Barbara L Asselin
Brent L Wood
Elizabeth A Raetz
John Murphy
Julie M Gastier-Foster
Marcia S Leonard Rn
Meenakshi Devidas
Mignon L Loh
Nancy Eisenberg
P2860
P304
P356
10.1002/PBC.25470
P577
2015-03-08T00:00:00Z